CL2021000389A1 - Formulaciones de dendrímeros. - Google Patents

Formulaciones de dendrímeros.

Info

Publication number
CL2021000389A1
CL2021000389A1 CL2021000389A CL2021000389A CL2021000389A1 CL 2021000389 A1 CL2021000389 A1 CL 2021000389A1 CL 2021000389 A CL2021000389 A CL 2021000389A CL 2021000389 A CL2021000389 A CL 2021000389A CL 2021000389 A1 CL2021000389 A1 CL 2021000389A1
Authority
CL
Chile
Prior art keywords
dendrimer formulations
dendrimer
formulations
kits
parts
Prior art date
Application number
CL2021000389A
Other languages
English (en)
Inventor
Paul Gellert
Kathryn Hill
Richard Storey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021000389A1 publication Critical patent/CL2021000389A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Abstract

COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN DENDRÍMERO LIOFILIZADO COVALENTEMENTE UNIDO A UN INHIBIDOR DE BCL; KIT DE PARTES; Y SU USO PARA TRATAR CÁNCER.
CL2021000389A 2018-08-17 2021-02-15 Formulaciones de dendrímeros. CL2021000389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719319P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
CL2021000389A1 true CL2021000389A1 (es) 2022-02-25

Family

ID=68084891

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000389A CL2021000389A1 (es) 2018-08-17 2021-02-15 Formulaciones de dendrímeros.

Country Status (22)

Country Link
US (1) US20220273677A1 (es)
EP (1) EP3837017A1 (es)
JP (1) JP2021534172A (es)
KR (1) KR20210046704A (es)
CN (1) CN112543664A (es)
AR (1) AR115983A1 (es)
AU (1) AU2019322205C1 (es)
BR (1) BR112021002586A2 (es)
CA (1) CA3108648A1 (es)
CL (1) CL2021000389A1 (es)
CO (1) CO2021002980A2 (es)
CR (1) CR20210086A (es)
DO (1) DOP2021000028A (es)
EA (1) EA202190458A1 (es)
IL (1) IL280829B1 (es)
MX (1) MX2021001831A (es)
PE (1) PE20210861A1 (es)
PH (1) PH12021550323A1 (es)
SG (1) SG11202101394YA (es)
TW (1) TW202021575A (es)
UY (1) UY38337A (es)
WO (1) WO2020035815A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104524596B (zh) * 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
LT2729179T (lt) * 2011-06-06 2020-12-28 Starpharma Pty Ltd Makromolekulės
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法

Also Published As

Publication number Publication date
US20220273677A1 (en) 2022-09-01
AU2019322205A1 (en) 2021-04-08
EP3837017A1 (en) 2021-06-23
DOP2021000028A (es) 2021-03-15
IL280829B1 (en) 2024-02-01
CO2021002980A2 (es) 2021-03-19
PH12021550323A1 (en) 2021-10-04
IL280829A (en) 2021-04-29
CA3108648A1 (en) 2020-02-20
CR20210086A (es) 2021-03-19
BR112021002586A2 (pt) 2021-05-04
WO2020035815A1 (en) 2020-02-20
JP2021534172A (ja) 2021-12-09
AU2019322205B2 (en) 2023-03-16
UY38337A (es) 2020-02-28
EA202190458A1 (ru) 2021-09-28
PE20210861A1 (es) 2021-05-18
TW202021575A (zh) 2020-06-16
AU2019322205C1 (en) 2023-09-07
MX2021001831A (es) 2021-04-28
SG11202101394YA (en) 2021-03-30
KR20210046704A (ko) 2021-04-28
CN112543664A (zh) 2021-03-23
AR115983A1 (es) 2021-03-17

Similar Documents

Publication Publication Date Title
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2022001671A1 (es) Inhibidores de sos1
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
BR112017012351A2 (pt) compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
PE20210685A1 (es) Anticuerpos que se dirigen al gp120 de vih y metodos de uso
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CR11139A (es) Anticuerpos anti-notch1 nrr y sus metodos de uso
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
CR10782A (es) Compuestos para inhibir la progresion mitotica
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
CO2022003703A2 (es) Conjugados terapéuticos